-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 17, Yan'an Bikang announced that the company's stock trading price increased for 3 consecutive trading days (August 12, 2022, August 15, 2022, and August 16, 2022.
The cumulative deviation value is more than 12.
According to the relevant provisions of the "Shenzhen Stock Exchange Trading Rules", it belongs to the abnormal fluctuation of stock tradin.
In response to the abnormal fluctuations in the company's stock trading, the company has checked the relevant matters, and asked the controlling shareholder and actual controlle.
The company has not found any recent public media reports that may or have had a greater impact on the company's stock trading pric.
material informatio.
In addition, the company stated that there is no information that needs to be corrected or supplemented in the information disclosed in the previous perio.
On the news, the company recently announced that it received the "Notification Letter" issued by the controlling shareholder on August 12, and learned that the controlling shareholder Xinyi Bikang and Guanghui Holdings signed the "Regarding the Investment in Xinyi Bikang New Pharmaceutical Industry Complex" on the same da.
Restructuring Investment Intention Agreement of 42 companies including C.
,Lt.
At present, 42 companies including Xinyi Bikang hold a total of 436% of the shares of *ST Bikan.
After friendly negotiation, the two parties reached a reorganization intention investment agreement on Guanghui Holdings' intention to participate in the reorganization investment of 42 companies including Xinyi Bikan.
Guanghui Holdings will provide financial support to listed companies in a timely manner by providing credit enhancement measures such as loans or guarantees, and increase the liquidity of listed companie.
Yan'an Bikang is a company whose main business includes four categories: pharmaceutical industry sector, pharmaceutical business sector, new energy and new material sector, and pharmaceutical intermediates (pharmaceutical intermediates, pesticide intermediates.
The analysis believes that the reorganization issued by Yan'an Bikang this time will, on the one hand, help the company to break through the difficulties of issuing bonds and illegal guarantees, and on the other hand, it will also help its new energy, new materials, medicine and other outlet industries long-term future
Among them, in the field of new energy and new materials, Yanan Bikang is the leading producer of lithium hexafluorophosphate in Chin.
At present, its lithium hexafluorophosphate expansion plan is expected to be implemented, and the company is actively exploring the international marke.
The lithium hexafluorophosphate market has broad prospect.
It is expected that the shortfall will exceed 60,000 tons in 2024, and Yan'an Bikang is expected to achieve rapid development through active layou.
At the same time, the company's ultra-high molecular polyethylene fiber expansion process is about to be complete.
According to statistics and forecast data from Grand View Research, the global ultra-high molecular weight polyethylene (UHWMPE) fiber market size was US$761 million in 2019, and is expected to grow to US$4067 billion by 2027, with a compound annual growth rate of 2020-202 6%, the market space is broa.
In addition, in the pharmaceutical sector, Yanan Bikang is seizing the general-purpose CAR-T track by taking a stake in Sunnyval.
Sunisell is an innovative drug research and development company based on cutting-edge gene editing technology, aiming to provide effective and affordable cell therapy drugs for cancer patients in Chin.
T) With the same efficacy and safety, the treatment cost can be reduced by 90%, and the efficacy is expected to break through the existing autologous CAR-T, prolong the recurrence time and improve the quality of life of patient.
The industry believes that the current general-purpose CAR-T is a cutting-edge trac.
Compared with the listed CAR-T, the price and cost are lowe.
If the general-purpose CAR-T cell therapy of Sunnyvale is successfully launched, the market value of Yan'an Bikang is expected to be expecte.
ushered in a marked ris.
On August 16, Yan'an Bikang closed at the daily limit, the stock price increased by 98%, and the closing price was 70 yua.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
The cumulative deviation value is more than 12.
According to the relevant provisions of the "Shenzhen Stock Exchange Trading Rules", it belongs to the abnormal fluctuation of stock tradin.
In response to the abnormal fluctuations in the company's stock trading, the company has checked the relevant matters, and asked the controlling shareholder and actual controlle.
The company has not found any recent public media reports that may or have had a greater impact on the company's stock trading pric.
material informatio.
In addition, the company stated that there is no information that needs to be corrected or supplemented in the information disclosed in the previous perio.
On the news, the company recently announced that it received the "Notification Letter" issued by the controlling shareholder on August 12, and learned that the controlling shareholder Xinyi Bikang and Guanghui Holdings signed the "Regarding the Investment in Xinyi Bikang New Pharmaceutical Industry Complex" on the same da.
Restructuring Investment Intention Agreement of 42 companies including C.
,Lt.
At present, 42 companies including Xinyi Bikang hold a total of 436% of the shares of *ST Bikan.
After friendly negotiation, the two parties reached a reorganization intention investment agreement on Guanghui Holdings' intention to participate in the reorganization investment of 42 companies including Xinyi Bikan.
Guanghui Holdings will provide financial support to listed companies in a timely manner by providing credit enhancement measures such as loans or guarantees, and increase the liquidity of listed companie.
Yan'an Bikang is a company whose main business includes four categories: pharmaceutical industry sector, pharmaceutical business sector, new energy and new material sector, and pharmaceutical intermediates (pharmaceutical intermediates, pesticide intermediates.
The analysis believes that the reorganization issued by Yan'an Bikang this time will, on the one hand, help the company to break through the difficulties of issuing bonds and illegal guarantees, and on the other hand, it will also help its new energy, new materials, medicine and other outlet industries long-term future
Among them, in the field of new energy and new materials, Yanan Bikang is the leading producer of lithium hexafluorophosphate in Chin.
At present, its lithium hexafluorophosphate expansion plan is expected to be implemented, and the company is actively exploring the international marke.
The lithium hexafluorophosphate market has broad prospect.
It is expected that the shortfall will exceed 60,000 tons in 2024, and Yan'an Bikang is expected to achieve rapid development through active layou.
At the same time, the company's ultra-high molecular polyethylene fiber expansion process is about to be complete.
According to statistics and forecast data from Grand View Research, the global ultra-high molecular weight polyethylene (UHWMPE) fiber market size was US$761 million in 2019, and is expected to grow to US$4067 billion by 2027, with a compound annual growth rate of 2020-202 6%, the market space is broa.
In addition, in the pharmaceutical sector, Yanan Bikang is seizing the general-purpose CAR-T track by taking a stake in Sunnyval.
Sunisell is an innovative drug research and development company based on cutting-edge gene editing technology, aiming to provide effective and affordable cell therapy drugs for cancer patients in Chin.
T) With the same efficacy and safety, the treatment cost can be reduced by 90%, and the efficacy is expected to break through the existing autologous CAR-T, prolong the recurrence time and improve the quality of life of patient.
The industry believes that the current general-purpose CAR-T is a cutting-edge trac.
Compared with the listed CAR-T, the price and cost are lowe.
If the general-purpose CAR-T cell therapy of Sunnyvale is successfully launched, the market value of Yan'an Bikang is expected to be expecte.
ushered in a marked ris.
On August 16, Yan'an Bikang closed at the daily limit, the stock price increased by 98%, and the closing price was 70 yua.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
